Vicente Anido, Jr.

2021

In 2021, Vicente Anido, Jr. earned a total compensation of $3.8M as Former Chief Executive Officer and Chairman of the Board at Aerie Pharmaceuticals, a 4% increase compared to previous year.

Compensation breakdown

Option Awards$1,458,192
Salary$581,024
Stock Awards$493,920
Other$1,240,014
Total$3,773,150

Anido received $1.5M in option awards, accounting for 39% of the total pay in 2021.

Anido also received $581K in salary, $493.9K in stock awards and $1.2M in other compensation.

Rankings

In 2021, Vicente Anido, Jr.'s compensation ranked 3,533rd out of 12,415 executives tracked by ExecPay. In other words, Anido earned more than 71.5% of executives.

ClassificationRankingPercentile
All
3,533
out of 12,415
72nd
Division
Manufacturing
1,449
out of 5,505
74th
Major group
Chemicals And Allied Products
587
out of 2,375
75th
Industry group
Drugs
524
out of 2,096
75th
Industry
Biological Products, Except Diagnostic Substances
137
out of 449
70th
Source: SEC filing on April 26, 2022.

Anido's colleagues

We found seven more compensation records of executives who worked with Vicente Anido, Jr. at Aerie Pharmaceuticals in 2021.

2021

Raj Kannan

Aerie Pharmaceuticals

Chief Executive Officer

2021

Thomas Mitro

Aerie Pharmaceuticals

Chief Operating Officer

2021

Casey Kopczynski

Aerie Pharmaceuticals

Chief Innovation Officer, Head of Research and External Innovation

2021

John LaRocca

Aerie Pharmaceuticals

General Counsel

2021

Benjamin McGraw

Aerie Pharmaceuticals

Former Interim Executive Chair

2021

Richard Rubino

Aerie Pharmaceuticals

Chief Financial Officer

2021

Christopher Staten

Aerie Pharmaceuticals

Chief Financial Officer

News

You may also like